Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
128.8 USD | +1.08% | +11.37% | +33.54% |
Sales 2024 * | 1.85B 148B | Sales 2025 * | 2.9B 232B | Capitalization | 12.17B 974B |
---|---|---|---|---|---|
Net income 2024 * | 214M 17.13B | Net income 2025 * | 1B 80.37B | EV / Sales 2024 * | 5.93 x |
Net cash position 2024 * | 1.2B 95.73B | Net cash position 2025 * | 2.59B 208B | EV / Sales 2025 * | 3.3 x |
P/E ratio 2024 * |
56.5
x | P/E ratio 2025 * |
12.4
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.13% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | +1.08% | ||
1 week | +11.37% | ||
Current month | -0.53% | ||
1 month | -1.12% | ||
3 months | +8.46% | ||
6 months | +20.54% | ||
Current year | +33.54% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 25/06/17 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 31/12/14 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 25/06/17 |
M. Wilsey
CHM | Chairman | 71 | 30/03/09 |
Richard Barry
BRD | Director/Board Member | 65 | 01/06/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | -5.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 128.8 | +1.08% | 1,236,000 |
25/04/24 | 127.4 | +2.53% | 1,694,410 |
24/04/24 | 124.2 | +6.09% | 1,500,200 |
23/04/24 | 117.1 | +0.14% | 568,912 |
22/04/24 | 117 | +1.16% | 889,164 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.54% | 12.17B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- SRPT Stock